NEW YORK (GenomeWeb News) – Upstream Biosciences yesterday said it has signed an option to buy Pacific Pharma Technologies, a company focused on drug development for parasitic diseases.
 
Upstream Biosciences, which develops genetic diagnostics for cancer and for predicting drug responses, said the agreement gives it an exclusive 3-month option to negotiate terms of the acquisition.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.